Lv3
370 积分 2023-05-05 加入
LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)
2小时前
已完结
Efficacy evaluation of postoperative adjuvant transarterial chemoembolization in preventing hepatocellular carcinoma recurrence within the Milan criteria: A multicenter propensity score matching analysis based on pathologic indicators
14小时前
求助中
Sorafenib versus transarterial chemoembolization as adjuvant therapies for patients with hepatocellular carcinoma and microvascular invasion
3个月前
已关闭
Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma
3个月前
已完结
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
1年前
已完结
Bone metastasis of hepatocellular carcinoma: facts and hopes from clinical and translational perspectives
1年前
已完结
LncRNA TCTN2 Promotes the Malignant Development of Hepatocellular Carcinoma via Regulating mIR-1285-3p/ARF6 Axis
1年前
已完结
Effects of an Antiadhesive Agent on Capsule Formation in Implant-Based Breast Reconstruction: A Randomized Controlled Trial
2年前
已完结
皖公网安备34019202002308
